---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-026410"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T14:51:04.760791+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FDA grants Fast Track Designation to Quoin's QRX003 for Netherton Syndrome

## Summary
- Fast Track Designation granted to QRX003 lotion (4%) for Netherton Syndrome, a rare genetic skin disorder with no approved treatments.
- QRX003 is currently in two late-stage whole-body clinical trials evaluating safety and efficacy in Netherton Syndrome patients.
- Previous designations include Orphan Drug Designation from FDA and EMA, and Pediatric Rare Disease Designation from FDA.
- Fast Track enables more frequent FDA interactions, rolling review, and potential Accelerated Approval or Priority Review.

## SEC filing metadata
- accession: 0001104659-26-026410
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465926026410/0001104659-26-026410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465926026410/tm268576d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-026410
- JSON: https://secwatch.observer/filing/0001104659-26-026410.json
- Plain text: https://secwatch.observer/filing/0001104659-26-026410.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.